Document is current
Any future updates will be listed below
-
Authors
Esposito, Daniela https://orcid.org/0000-0001-8993-2071
Boguszewski, Cesar Luiz https://orcid.org/0000-0001-7285-7941
Colao, Annamaria
Fleseriu, Maria https://orcid.org/0000-0001-9284-6289
Gatto, Federico https://orcid.org/0000-0002-5062-9208
Jørgensen, Jens Otto Lunde https://orcid.org/0000-0001-7408-1526
Ragnarsson, Oskar
Ferone, Diego https://orcid.org/0000-0002-1410-6143
Johannsson, Gudmundur https://orcid.org/0000-0003-3484-8440
- License Information
-
More Information
Article History
Accepted: 22 April 2024
First Online: 6 June 2024
Competing interests
: D.E. has received lecture fees from Ipsen and Pfizer AB. C.L.B. has received lecture fees from Ipsen, Recordati and Novo Nordisk, has been Principal Investigator of Research Studies for Novartis and Recordati, and served as consultant for Ipsen, Recordati, Crinetics, and Novo Nordisk. A.C. has been Principal Investigator of Research Studies for Novartis, Ipsen, Pfizer, Lilly, Merck and Novo Nordisk, a consultant for Novartis, Ipsen, and Pfizer, and received honoraria from Novartis, Ipsen and Pfizer. M.F. has received grants to their institution from Amryt, Crinetics, Ionis, and Recordati and has received occasional consulting fees or has served as occasional Advisory Board Member for Amryt, Camurus, Ipsen, Pfizer, and Recordati. F.G. has received lecture/manuscript writing fees from Recordati Rare Diseases, Camurus, Ipsen and Pfizer. J.O.L.J. has served as Advisory Board Member for Novo Nordisk. D.F. has received lecture, advisory board and steering committee fees as well as a research grant from Recordati Rare Diseases, Camurus, Novartis-Advanced Accelerator Applications, Ipsen, and Bristol Myers Squibb. G.J. has served as a consultant for Novo Nordisk, Shire, and Astra Zeneca and has received lecture fees from Eli Lilly, Ipsen, Novartis, Novo Nordisk, Merck Serono, Otsuka, and Pfizer AB. The other authors declare no competing interests.
